Integrin avb3 a potential prognostic biomarker of chemotherapy response in breast cancer

DÍAZ ALBUJA JA; STERLE HA; CAYROL F; PAULAZO MA; CAMPOS HAEDO MN; DEBERNARDI MM; ROSEMBLIT C; CREMASCHI GA; DÍAZ FLAQUÉ MC

virtual

Congreso; SAFIS + ALACF 2021 Joint meeting; 2021

Sociedad Argentina de Fisiología

Despite the development of novel therapies, breast cancer (BC) tumors are treated with conventional therapy sooner or later.Due to tumor heterogeneity, it is necessary to define new biomarkers to identify groups with different molecular characterist icto improve the correct treatment decision. The impact of thyroid status in BC growth has previously been studied. It has beenfound alterations of thyroid function during chemotherapy BC treatment and demonstrated that T3 induces chemosensitizationof BC cells. However, the relationship between thyroid hormones (THs) membrane receptor, integrin αvβ3 and BC response tochemotherapy remains unclear. The aim of this study is to evaluate the relationship between THs and integrin αvβ3 expressionas prognostic value in BC patients. The mRNA expression of ITGB3 in TCGA-PanCancer Atlas, BC dataset (1084 patients) werecorrelated with ABCB1 and ABCG2, (Pearson, R score >0.3 and p